An interventional study of transcranial direct current stimulation in Epilepsy and Drug Resistant Epilepsy, sponsored by Assistance Publique Hopitaux De Marseille. Recruiting at 7 sites in France. Open to participants aged 9 Years and older. Per ClinicalTrials.gov, last updated 2025-12-19.
Sponsored by Assistance Publique Hopitaux De Marseille · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 35 studies in Drug Resistant Epilepsy with a site in France — 16 open to participants now, 17 under way, 1 of them phase 3. Drug Resistant Epilepsy · France.
Among the 35 studies in Drug Resistant Epilepsy with a site in France, this one is the 15th largest by planned enrollment of the 24 interventional ones that give a count, is one of 7 that started in 2024, is one of 12 with no phase, reaches primary completion later than 3 of the 16 other live ones, and was the 28th registered.
258 studies on the registry are indexed under Drug Resistant Epilepsy; 109 are open to participants now.
Browse Drug Resistant Epilepsy studies →16 of the 35 studies in Drug Resistant Epilepsy with a site in France are open now. Recruiting first, the newest first:
Assistance Publique Hopitaux De Marseille · Sites in France
Ages 12+
Hospices Civils de Lyon · Sites in France
Ages 18–60 · Healthy volunteers
University Hospital, Strasbourg, France · Sites in France
Ages 5–25
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18–65
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 68 Drug Resistant Epilepsy studies recruiting now, 27 (40%) set no upper age limit and 40 (59%) stop at 75 or younger; 27 take children under 18; 6 take healthy volunteers.
This study: 9 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
35 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 8 · Phase 3 8
First in 2005; this study’s year is marked. 7 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is above the median of 30 across 202 interventional studies indexed under Drug Resistant Epilepsy.
Median enrollment 82 across the 24 interventional studies, 110 across the 11 observational. Of the 14 that completed or were terminated, 5 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 35 have an industry lead sponsor. The 10 most frequent:
Assistance Publique Hopitaux De Marseille is the lead sponsor of 702 studies on the registry; 139 are open to participants now.
Assistance Publique Hopitaux De Marseille has 4 studies filed under Drug Resistant Epilepsy — fewer than ten, so there is no comparison to draw.
6 of the studies in Drug Resistant Epilepsy with a site in France that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06132893Phase 3Biohaven Therapeutics Ltd.A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy | 2026-12 |
| NCT06443463Biohaven Therapeutics Ltd.Long-term Safety and Tolerability of BHV-7000 | 2026-12 |
| NCT06334952Assistance Publique Hopitaux De MarseilleEfficacy of Personnalized Transcranial Direct Current Electrical Stimulation (tDCS) in Drug-resistant Epileptic | 2026-12-18 |
| NCT06138808Duke University5-SENSE Score Validation Study | 2027-01 |
| NCT07898397University Hospital, Strasbourg, FranceLong-Term Epilepsy Outcomes in Children With a History of Perinatal Stroke | 2027-02-28 |
Add all 6 to your calendar (.ics) → With an account.
Among the 35 studies in Drug Resistant Epilepsy with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to to obtain a significant decrease in seizure frequency in patients with refractory focal epilepsy after applying treatment of cathodal tDCS, compared to sham stimulation drug-resistant epileptic patient. The main questions it aims to answer are:
258 studies on the registry are indexed under Drug Resistant Epilepsy; 109 are open to participants now.
This study's planned enrollment of 60 is above the median of 30 across 202 interventional studies indexed under Drug Resistant Epilepsy.
Browse Drug Resistant Epilepsy studies →Assistance Publique Hopitaux De Marseille is the lead sponsor of 702 studies on the registry; 139 are open to participants now.
Compared within Drug Resistant Epilepsy, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Epilepsy. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patient will be randomized to firstly receive tDCS (10 non consecutive days, 20 minutes twice a day with 20 minutes of break) and then Sham (10 non consecutive days, 20 minutes twice a day with 20 minutes of break).
Device: transcranial direct current stimulation
Patient will be randomized to firstly receive Sham (10 non consecutive days, 20 minutes twice a day with 20 minutes of break) and then tDCS (10 non consecutive days, 20 minutes twice a day with 20 minutes of break).
Device: transcranial direct current stimulation
Research MRI includes 3D-T1 weighted MRI (3D-T1), diffusion MRI (dMRI), resting-state functional MRI (rsfMRI).
Also known as: Research MRI, EEG
To obtain a significant seizure frequency change at the end of tDCS sessions compared to the seizure frequency calculated in the pre-treatment period of reference.
Seizure frequency counting after end of tDCS treatment compared to the baseline comparing Sham versus Active arms of the cross-over study.
Time frame: Visit 4 (V4) - 4 weeks after the end of first cycle (each cycle is 10 days)
To obtain a significant seizure frequency change at the end of tDCS sessions compared to the seizure frequency calculated in the pre-treatment period of reference.
Seizure frequency counting after end of tDCS treatment compared to the baseline comparing Sham versus Active arms of the cross-over study.
Time frame: V5 - 8 weeks after the end of first cycle (each cycle is 10 days)
To obtain a significant seizure frequency change at the end of tDCS sessions compared to the seizure frequency calculated in the pre-treatment period of reference.
Seizure frequency counting after end of tDCS treatment compared to the baseline comparing Sham versus Active arms of the cross-over study.
Time frame: V7 - 4 weeks after the end of the second cycle (each cycle is 10 days)
To obtain a significant seizure frequency change at the end of tDCS sessions compared to the seizure frequency calculated in the pre-treatment period of reference.
Seizure frequency counting after end of tDCS treatment compared to the baseline comparing Sham versus Active arms of the cross-over study.
Time frame: V8 - 8 weeks after the end of the second cycle (each cycle is 10 days)
Evaluation of the number of responders (defined as patient with >50% of seizure reduction)
Proportion of responders evaluated after active session of 10 days of tDCS treatment compared to the baseline comparing Sham versus Active arms of the cross-over study
Time frame: Visit 4 (V4) - 4 weeks after the end of first cycle (each cycle is 10 days)
Evaluation of the number of responders (defined as patient with >50% of seizure reduction)
Proportion of responders evaluated after active session of 10 days of tDCS treatment compared to the baseline comparing Sham versus Active arms of the cross-over study
Time frame: V5 - 8 weeks after the end of first cycle (each cycle is 10 days)
Evaluation of the number of responders (defined as patient with >50% of seizure reduction)
Proportion of responders evaluated after active session of 10 days of tDCS treatment compared to the baseline comparing Sham versus Active arms of the cross-over study
Time frame: V7 - 4 weeks after the end of the second cycle (each cycle is 10 days)
Evaluation of the number of responders (defined as patient with >50% of seizure reduction)
Proportion of responders evaluated after active session of 10 days of tDCS treatment compared to the baseline comparing Sham versus Active arms of the cross-over study
Time frame: V8 - 8 weeks after the end of the second cycle (each cycle is 10 days)
Evaluate the number of seizure-free patients
Number of seizure-free patients after active session of 10 days of tDCS treatment compared to the baseline comparing Sham versus Active arms of the cross-over study
Time frame: Visit 4 (V4) - 4 weeks after the end of first cycle (each cycle is 10 days)
Evaluate the number of seizure-free patients
Number of seizure-free patients after active session of 10 days of tDCS treatment compared to the baseline comparing Sham versus Active arms of the cross-over study
Time frame: V5 - 8 weeks after the end of first cycle (each cycle is 10 days)
Evaluate the number of seizure-free patients
Number of seizure-free patients after active session of 10 days of tDCS treatment compared to the baseline comparing Sham versus Active arms of the cross-over study
Time frame: V7 - 4 weeks after the end of the second cycle (each cycle is 10 days)
Evaluate the number of seizure-free patients
Number of seizure-free patients after active session of 10 days of tDCS treatment compared to the baseline comparing Sham versus Active arms of the cross-over study
Time frame: V8 - 8 weeks after the end of the second cycle (each cycle is 10 days)
Quality of life after stimulation sessions with the baseline period
Changes from baseline in the quality of life questionnaire (QOLIE 31 for adults and EFIQUACEE QOL for children) after the stimulation period
Time frame: Visit 4 (V4) - 4 weeks after the end of first cycle (each cycle is 10 days)
Quality of life after stimulation sessions with the baseline period
Changes from baseline in the quality of life questionnaire (QOLIE 31 for adults and EFIQUACEE QOL for children) after the stimulation period
Time frame: V5 - 8 weeks after the end of first cycle (each cycle is 10 days)
Quality of life after stimulation sessions with the baseline period
Changes from baseline in the quality of life questionnaire (QOLIE 31 for adults and EFIQUACEE QOL for children) after the stimulation period
Time frame: V7 - 4 weeks after the end of the second cycle (each cycle is 10 days)
Quality of life after stimulation sessions with the baseline period
Changes from baseline in the quality of life questionnaire (QOLIE 31 for adults and EFIQUACEE QOL for children) after the stimulation period
Time frame: V8 - 8 weeks after the end of the second cycle (each cycle is 10 days)
Evaluation of the change in seizure severity
Changes in the scores of epilepsy severity (NHS3) (investigator evaluation)
Time frame: Visit 4 (V4) - 4 weeks after the end of first cycle (each cycle is 10 days)
Evaluation of the change in seizure severity
Changes in the scores of epilepsy severity (NHS3) (investigator evaluation)
Time frame: V5 - 8 weeks after the end of first cycle (each cycle is 10 days)
Evaluation of the change in seizure severity
Changes in the scores of epilepsy severity (NHS3) (investigator evaluation)
Time frame: V7 - 4 weeks after the end of the second cycle (each cycle is 10 days)
Evaluation of the change in seizure severity
Changes in the scores of epilepsy severity (NHS3) (investigator evaluation)
Time frame: V8 - 8 weeks after the end of the second cycle (each cycle is 10 days)
Changes in psychiatric comorbidities
Changes from baseline in depression (NDDI-E) and anxiety (GAD-7) scores
Time frame: Visit 4 (V4) - 4 weeks after the end of first cycle (each cycle is 10 days)
Changes in psychiatric comorbidities
Changes from baseline in depression (NDDI-E) and anxiety (GAD-7) scores
Time frame: V5 - 8 weeks after the end of first cycle (each cycle is 10 days)
Changes in psychiatric comorbidities
Changes from baseline in depression (NDDI-E) and anxiety (GAD-7) scores
Time frame: V7 - 4 weeks after the end of the second cycle (each cycle is 10 days)
Changes in psychiatric comorbidities
Changes from baseline in depression (NDDI-E) and anxiety (GAD-7) scores
Time frame: V8 - 8 weeks after the end of the second cycle (each cycle is 10 days)
Safety assessment and possible side effects
Percent of newly reported side-effect during and after the stimulation period
Time frame: Visit 4 (V4) - 4 weeks after the end of first cycle (each cycle is 10 days)
Safety assessment and possible side effects
Percent of newly reported side-effect during and after the stimulation period
Time frame: V5 - 8 weeks after the end of first cycle (each cycle is 10 days)
Safety assessment and possible side effects
Percent of newly reported side-effect during and after the stimulation period
Time frame: V7 - 4 weeks after the end of the second cycle (each cycle is 10 days)
Safety assessment and possible side effects
Percent of newly reported side-effect during and after the stimulation period
Time frame: V8 - 8 weeks after the end of the second cycle (each cycle is 10 days)
Compare brain functional connectivity before and after tDCS treatment
Changes in functional connectivity measured by fMRI and EEG signal 4 weeks after the tDCS periods in comparison with baseline period
Time frame: V5 - 8 weeks after the end of first cycle (each cycle is 10 days)
Evaluation of the impact of tDCS on interictal epileptic spikes (IESs)
Change in the number of IESs per time unit after each tDCS session in comparison with baseline period
Time frame: Visit 4 (V4) - 4 weeks after the end of first cycle (each cycle is 10 days)
Evaluation of the impact of tDCS on interictal epileptic spikes
Change in localization and extent of brain areas involved in IESs before and after each tDCS session in comparison with baseline period
Time frame: Visit 4 (V4) - 4 weeks after the end of first cycle (each cycle is 10 days)
Evaluation of the impact of tDCS on interictal epileptic spikes
Change in localization and extent of brain areas involved in IESs before and after each tDCS session in comparison with baseline period
Time frame: V7 - 4 weeks after the end of the second cycle (each cycle is 10 days)
Evaluation of the impact of tDCS on interictal epileptic spikes
Changes in strength and density of functional links during IES before and after each tDCS session
Time frame: Visit 4 (V4) - 4 weeks after the end of first cycle (each cycle is 10 days)
Evaluation of the impact of tDCS on interictal epileptic spikes
Changes in strength and density of functional links during IES before and after each DCS session
Time frame: V7 - 4 weeks after the end of the second cycle (each cycle is 10 days)
Plan to share: No
No publications or documents are linked to this record.
Started Dec 2024 (actual). Primary completion is estimated for Dec 2026, 24 months after the start.
Of 90 non-industry interventional studies with no phase under Drug Resistant Epilepsy, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 21. This study's planned 24 months is below that.
Counting every sponsor, half of 102 studies reached it within 34 months; a quarter within 21 and three quarters within 50.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Assistance Publique Hopitaux De Marseille →